Premium
Low‐density lipoprotein and other predictors of response with telaprevir‐based therapy in treatment‐experienced HCV genotype 1 patients: REALIZE study
Author(s) -
Berg Thomas,
Andreone Pietro,
Pol Stanislas,
Roberts Stuart,
Younossi Zobair,
Diago Moises,
Lawitz Eric J.,
Focaccia Roberto,
Foster Graham R.,
Horban Andrzej,
LonjonDomanec Isabelle,
DeMasi Ralph,
Picchio Gaston,
Luo Donghan,
De Meyer Sandra,
Zeuzem Stefan
Publication year - 2015
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/liv.12703
Subject(s) - telaprevir , medicine , ribavirin , confidence interval , odds ratio , post hoc analysis , gastroenterology , multivariate analysis , logistic regression , univariate analysis , immunology , hepatitis c virus , virus
Background & Aims Predictors of response to treatment with peginterferon plus ribavirin are well established. In these post‐hoc analyses of the REALIZE study, we sought to identify predictors of response for telaprevir‐based triple therapy. Methods Patients from the REALIZE study with baseline data for all predictors evaluated (including baseline disease characteristics and demographics, prior treatment response and baseline laboratory assessments) were included in the post‐hoc analyses ( n = 465). Univariate and multivariate analyses were used to evaluate factors predicting treatment outcomes. Results Sustained viral response ( SVR ) rates were 86% in prior relapsers, 63% in prior partial responders and 32% in prior null‐responders. In the final multivariate analysis, baseline factors predicting SVR were prior response to treatment [Odds ratio ( OR ) = 2.80; 95% confidence interval ( CI ), 2.13–3.69], low‐density lipoprotein ( LDL ) (≥2.6 mmol/L) ( OR = 2.11; 95% CI , 1.52–2.93), HCV genotype ( OR = 0.58; 95% CI , 0.36–0.93), and maximum alanine amino transferase and aspartate amino transferase ( OR = 0.62; 95% CI , 0.40–0.97). Conclusions Prior response to peginterferon plus ribavirin treatment and LDL levels are the main independent predictive markers of response with telaprevir‐based triple therapy.